* Transmedics Group Inc TMDX.OQ TMDX.O is expected
to show a
rise in quarterly revenue when it reports results on April 30
for the period ending March 31 2024
* The Andover Massachusetts-based company is expected to
report a
101.6% increase in revenue to $83.778 million from $41.55
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Transmedics Group Inc is
for a
loss of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Transmedics
Group
Inc is $100.00, above its last closing price of $92.08.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.03 -0.03 0.12 Beat 500
Sep. 30 2023 -0.16 -0.16 -0.78 Missed -382.5
Jun. 30 2023 -0.11 -0.13 -0.03 Beat 76.9
Mar. 31 2023 -0.21 -0.25 -0.08 Beat 67.5
Dec. -0.30 -0.30 -0.21 Beat 30
31 2022
Sep. 30 2022 -0.43 -0.41 -0.25 Beat 39.3
Jun. 30 2022 -0.35 -0.35 -0.41 Missed -17.8
Mar. 31 2022 -0.39 -0.38 -0.38 Met 0
This summary was machine generated April 26 at 21:44 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)